Stem-cell chairman takes on wider role
By Carl T. Hall,
San Francisco Chronicle
| 01. 07. 2005
Board names Klein president, gives him authority to hire staff
Robert N. Klein, the Palo Alto developer and stem-cell advocate, took on the crucial day-to-day management duties Thursday for California's $3 billion stem-cell program.
Klein, who already was serving as chairman of the 29-member oversight board directing the voter-approved California Institute for Regenerative Medicine, was named by that board to be interim president of the institute with authority to hire staff and find office space.
State voters created the institute in November by passing Proposition 71, which authorized up to $350 million a year in taxpayer-financed bonds to pay for research projects and facilities during the next decade. The main purpose of the grants will be to promote embryonic stem-cell research that can't be financed by the federal government under rules adopted by the Bush administration.
Stem cells are the early, undifferentiated cells that eventually turn into the many specific cell types of the body. Biologists say the cells are invaluable research tools that might be fashioned into cures for diseases that can't otherwise be treated effectively. Religious and other...
Related Articles
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Ed Pilkington, The Guardian | 06.12.2026
Desperate US parents paying up to $20,000 a session for a procedure scientists say could be bogus
Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and...
By Tobi Thomas, The Guardian | 06.10.2026
The UK’s stem cell transplant system is potentially putting the lives of blood cancer patients at risk as a result of inadequate infrastructure and a lack of long-term planning, a parliamentary report has found.
A hematopoietic stem cell transplant, often...